Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor (Will-Plate)

Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.

hemostatic
prasugrel
clopidogrel
ticagrelor
coagulation factor
  • 0 views
  • 06 May, 2022
  • 1 location
DOT HeartMate 3 Study

A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.

  • 0 views
  • 21 Apr, 2022
  • 1 location
Adjusted Fibrinogen Replacement Strategy (AdFIrst)

The purpose of this study is to investigate efficacy and safety of fibrinogen concentrate BT524, when administered to patients with major blood loss during elective spine surgery.The study aims to demonstrate that BT524 is at least not worse than the comparator fresh frozen plasma in reducing intra-operative blood loss.

blood transfusion
fibrinogen
  • 10 views
  • 26 Apr, 2022
  • 3 locations
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

The primary objectives of the study are to further evaluate the efficacy and safety of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in adolescent and adult

  • 0 views
  • 26 Apr, 2021
  • 16 locations
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be

severe haemophilia a
coagulation factor
antihemophilic factor
  • 0 views
  • 05 Mar, 2022
  • 1 location
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation (ERSAF)

> Rivaroxaban, a direct coagulation factor Ⅹa inhibitor, blocks the formation of the clot. ROCKET-AF study has shown that the efficacy of rivaroxaban is not inferior to that of warfarin in AF patients on stroke

deficit
anticoagulants
warfarin
infarct
diabetes
  • 13 views
  • 11 Mar, 2022
  • 1 location
Factor In the Initial Resuscitation of Severe Trauma 2 Patients

(PCC)- European standard Strategies for hemorrhage and coagulopathy treatment have changed significantly over the last decade. Prompt hemorrhage control, along with targeted coagulation

  • 0 views
  • 18 Oct, 2021
  • 4 locations
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

This is a Phase I study. This research study is being conducted to find new ways to treat severe hemophilia A. This study is a gene therapy study. Gene therapy is an experimental way to introduce, into a person's cells, specific genetic material. A gene can be delivered/introduced into a …

severe haemophilia a
cirrhosis
renal function
factor viii inhibitor
total bilirubin
  • 10 views
  • 31 Oct, 2021
  • 1 location
Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation (OPSTAHT)

This study is comparing the use of Kcentra vs. standard transfusion in patients undergoing heart transplantation surgery. Half of the patients will receive Kcentra, while the other half will receive fresh frozen plasma.

heart transplantation
  • 7 views
  • 23 Mar, 2022
  • 2 locations
Gene Therapy for Haemophilia A.

The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A

bleeding tendency
severe haemophilia a
joint pain
arthropathy
antihemophilic factor
  • 301 views
  • 24 Jan, 2021
  • 3 locations